08:38 AM EST, 11/13/2025 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) said Thursday that second-quarter net loss widened.

Net loss was $4.9 million or $0.06 per share compared to a net loss of $4.2 million or $0.05 per share for the prior year period. The increase was mainly due to a smaller gain on the fair value of the derivative warrant liability of $1 million.

The company exited the quarter with $15.7 million cash, which is expected to provide it with enough capital through the middle of next year.